Relative to prostate-specific antigen (PSA), our mRNA-based diagnostic emerges as a more dependable biomarker, with an accuracy rate exceeding 90%, and readily repeatable while providing real-time information.
The NETest, a multigene blood biomarker, is more accurate at predicting recurrence in NET resection surgery patients, providing greater efficiency for oncologists in managing neuroendocrine cancer treatment.
Recent research published in the Journal of Nuclear Medicine (April '23) has validated the NETest and PPQ as a predictor of PRRT effectiveness in treating some NETs.
